Roberto Cauda to Anti-HIV Agents
This is a "connection" page, showing publications Roberto Cauda has written about Anti-HIV Agents.
Connection Strength
0.479
-
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
Score: 0.074
-
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018 07 01; 73(7):1949-1954.
Score: 0.074
-
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir. Antivir Ther. 2018; 23(2):139-148.
Score: 0.071
-
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. J Antimicrob Chemother. 2017 07 01; 72(7):2055-2059.
Score: 0.069
-
Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries??. Int J Clin Pharmacol Ther. 2017 May; 55(5):381-393.
Score: 0.068
-
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. J Chemother. 2017 Oct; 29(5):299-307.
Score: 0.066
-
Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1. Curr HIV Res. 2008 Jun; 6(4):306-17.
Score: 0.037
-
People Living with HIV in the COVID-19 Era: A Case Report. AIDS Res Hum Retroviruses. 2021 04; 37(4):253-254.
Score: 0.021